Related Experiment Video
Updated: Jun 28, 2026
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Miscreant myeloproliferative disorder stem cells
C H M Jamieson1, C F Barroga, W P Vainchenker
1Department of Medicine, Moores UCSD Cancer Center San Diego Medical Center, University of California, La Jolla, CA 92093-0820, USA. cjamieson@ucsd.edu
Abstract:
Myeloproliferative disorders (MPDs), typified by robust marrow and extramedullary hematopoiesis, have a propensity to progress to acute leukemia. Although the hematopoietic stem cell (HSC) origin of MPDs was suggested over 30 years ago, only recently the HSC-specific effects of MPD molecular mutations have been investigated. The pivotal role of BCR-ABL in chronic myeloid leukemia (CML) development provided the rationale for targeted therapy, which greatly reduced mortality rates. However, BCR-ABL inhibitor-resistant CML HSCs persist that may be a reservoir for relapse. This has provided the impetus for investigating molecular mechanisms governing the production of recalcitrant HSC. Comparatively little was known about the molecular events driving BCR-ABL-negative MPDs until seminal studies revealed that a large proportion of MPD patients harbor a JAK2-activating point mutation, JAK2V617F. Although JAK2 activation appears to be central to BCR-ABL-negative MPD pathogenesis, its effects may be cell type and context specific. Recent evidence suggests that acquired mutations misdirect differentiation and survival of the MPD-initiating stem cell resulting in the production of aberrant self-renewing progenitors that subvert the microenvironment leading to leukemia stem cell generation and leukemic transformation. Thus, combined therapies targeting aberrant molecular pathways may be required to redirect miscreant MPD stem cells.
Insights
Myeloproliferative disorders (MPDs) originate from hematopoietic stem cells (HSCs) and can progress to acute leukemia. Targeting molecular mutations like JAK2V617F is crucial for developing effective MPD therapies.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- Myeloproliferative disorders (MPDs) are characterized by excessive blood cell production and can transform into acute leukemia.
- Hematopoietic stem cell (HSC) origin of MPDs is established, with recent focus on HSC-specific molecular mutations.
- Chronic myeloid leukemia (CML) driven by BCR-ABL led to targeted therapies, but resistant HSCs remain a challenge.
Purpose of the Study:
- Investigate the molecular mechanisms driving MPD pathogenesis, particularly in BCR-ABL-negative cases.
- Understand the role of JAK2 mutations in MPD development and leukemic transformation.
- Identify strategies to redirect aberrant MPD stem cells towards normal differentiation.
Main Methods:
- Review of recent studies on molecular mutations in MPDs.
- Analysis of JAK2V617F mutation's role in BCR-ABL-negative MPDs.
- Examination of stem cell differentiation and survival pathways in MPD.
Main Results:
- JAK2 activation, specifically the JAK2V617F mutation, is central to BCR-ABL-negative MPD pathogenesis.
- Acquired mutations disrupt HSC differentiation and survival, leading to self-renewing progenitors.
- These aberrant progenitors contribute to leukemic stem cell generation and transformation.
Conclusions:
- Targeting molecular pathways in MPDs is essential for preventing leukemic transformation.
- Combined therapies may be necessary to address the complexity of MPD stem cell dysfunction.
- Further research into JAK2 signaling and stem cell behavior is critical for therapeutic advancements.
Related Concept Videos
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
01:15Differentiation of Common Myeloid Progenitor Cells
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
01:01Regulation of Hematopoietic Stem Cells